Risks to Sponsors Developing and Running Their Own DCT Technology
With decentralized clinical trials (DCTs) becoming more prevalent and both sites and patients showing their enthusiasm and support for the model, sponsors are seeking to expand their use in their portfolios of clinical trials. To keep up with the changes, many sponsors are evaluating their DCT technology needs as they look to license, purchase, or build their own DCT technology systems.
Scrip, in partnership with IQVIA, presents a look at what it really takes to run a “home grown” DCT solution, and examines the complexities to consider when licensing existing DCT technology.